(1R,2R,6S)-3-Methyl-6-(3-(4-phenylpiperidin-1-yl)prop-1-en-2-yl)cyclohex-3-ene-1,2-diol
Parkinson’s disease (PD) is a progressive neurodegenerative disorder whose primary manifestation is motor dysfunction. Previous research showed that (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol (Prottremine) exhibits potent antiparkinsonian activity in animal models of PD, with an efficacy comparable to levodopa. Herein, we report the synthesis of a new Prottremine derivative, (1R,2R,6S)-3-methyl-6-(3-(4-phenylpiperidin-1-yl)prop-1-en-2-yl)cyclohex-3-ene-1,2-diol. The compound was fully characterized and its structure was confirmed through single-crystal X-ray diffraction analysis.
Authors
- Tatyana V. Rybalova (ORCID: https://orcid.org/0000-0003-2398-5271)
- Николай С. Ли-Жуланов (ORCID: https://orcid.org/0000-0003-3555-2481)
- Alexandra V. Podturkina (ORCID: https://orcid.org/0009-0000-3511-3716)
- Константин П. Волчо (ORCID: https://orcid.org/0000-0002-4083-9324)
- Нариман Ф. Салахутдинов (ORCID: https://orcid.org/0000-0001-8512-4309)
Institutions
- Novosibirsk Institute of Organic Chemistry (RU)
Publication Details
- Journal
- Molbank
- Published
- 2025-11-12
- DOI
- https://doi.org/10.3390/m2088
- Citations
- 1
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Siberian Branch, Russian Academy of Sciences
- Russian Science Foundation